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Significance statementThis article documents that cardiac chamber enlargement postinfarction is a predictor of cardiopoietic stem cell therapy response. Left ventricular size pretherapy could thus serve to guide the selection of ischemic heart failure candidates most suitable to receive a regenerative intervention.

1. INTRODUCTION {#sct312577-sec-0003}
===============

Stem cell therapy aims at restoring organ structure and function in the setting of ischemic heart failure, a leading cause of morbidity and mortality.[1](#sct312577-bib-0001){ref-type="ref"} The feasibility and safety of delivering stem cell biotherapies in infarcted hearts are established, yet a pressing challenge is the observed heterogeneity in outcomes.[2](#sct312577-bib-0002){ref-type="ref"} A practical approach to segregate potential responders from non‐responders would contribute to standardized adoption.[3](#sct312577-bib-0003){ref-type="ref"}, [4](#sct312577-bib-0004){ref-type="ref"}, [5](#sct312577-bib-0005){ref-type="ref"}

Indeed, defining the guiding criteria for selection of best candidates prior to cell intervention is warranted.[6](#sct312577-bib-0006){ref-type="ref"}, [7](#sct312577-bib-0007){ref-type="ref"}, [8](#sct312577-bib-0008){ref-type="ref"} In heart failure, a recognized indicator of successful management is the reversal of left ventricular (LV) dilatation.[9](#sct312577-bib-0009){ref-type="ref"}, [10](#sct312577-bib-0010){ref-type="ref"}, [11](#sct312577-bib-0011){ref-type="ref"} Accordingly, this study assessed the predictive value of LV volume in the context of stem cell therapy for ischemic cardiomyopathy.

2. MATERIALS AND METHODS {#sct312577-sec-0004}
========================

2.1. Model {#sct312577-sec-0005}
----------

Institutional Animal Care and Use Committee approved protocols were used. C57BL/6 or athymic nude mice (8 to 12 week old) underwent permanent ligation or 75‐minutes occlusion followed by reperfusion of the left anterior descending coronary artery. One month postinfarction, surviving animals (n = 50) were randomized 1:1 into sham‐treated (n = 25, 7 athymic nude, 18 C57BL/6) and cell‐treated (n = 25 athymic nude) cohorts. Of note, cardiomyopathic phenotype postmyocardial infarction was equivalent in C57BL/6 vs athymic mice.

To limit cell‐related variability, cardiopoietic stem (CP) cells served as a prototype of clinically tested regenerative biotherapy.[12](#sct312577-bib-0012){ref-type="ref"} Human CP cells were generated from bone marrow‐derived mesenchymal stem cells following an established cardiopoiesis lineage‐specifying protocol.[13](#sct312577-bib-0013){ref-type="ref"}, [14](#sct312577-bib-0014){ref-type="ref"} CP cells (600 000 cells per heart in 15 μl media) were epicardially microinjected into 6 peri‐infarcted sites of the LV anterior wall.[15](#sct312577-bib-0015){ref-type="ref"} The same procedure without cells (15 μl media injection into 6 sites) was applied to the sham cohort.

2.2. Endpoints {#sct312577-sec-0006}
--------------

Therapeutic efficacy was assessed noninvasively by transthoracic echocardiography (Vevo3100 with MX400, Vevo2100 with MS400, FUJIFILM VisualSonics, Toronto, Canada) with prospective evaluation at preinfarction, 1 month postinfarction (pre‐cell therapy), and 1 month post‐cell therapy. LV ejection fraction (EF) was calculated as EF% = 100 × (LVEDV‐LVESV)/LVEDV.[16](#sct312577-bib-0016){ref-type="ref"} EF improvement or worsening, within 1 month after cell therapy, was preset at \>4% absolute increase and decrease, respectively, in line with clinical trial design.[17](#sct312577-bib-0017){ref-type="ref"} Reverse remodeling was defined by \>15% reduction in LVESV.[18](#sct312577-bib-0018){ref-type="ref"} Echocardiographic data were independently analyzed in an investigator‐blinded fashion by board‐certified cardiologists/sonographers.

2.3. Proteomics {#sct312577-sec-0007}
---------------

At the end of the 2 month follow‐up, LV protein extracts were analyzed by label‐free quantitative tandem mass spectrometry, with resulting differentially expressed proteins (\>twofold change, *p* \< .05) interpreted by Ingenuity Pathway Analysis for response to functional or adverse cardiac effects[19](#sct312577-bib-0019){ref-type="ref"}, [20](#sct312577-bib-0020){ref-type="ref"} induced by myocardial infarction with or without CP therapy.

2.4. Statistics {#sct312577-sec-0008}
---------------

The nonparametric Mann‐Whitney *U* test or two‐way repeated‐measures ANOVA was used to evaluate significance between treatment arms (JMP Pro 14.1.0, SAS Institute Inc., Cary, North Carolina). Data are presented as mean ± SEM. A *p*‐value \<.05 was considered significant.

3. RESULTS {#sct312577-sec-0009}
==========

Coronary ligation increased LVEDV from 43 ± 1 μl preinfarction to 77 ± 4 μl 1 month postinfarction (n = 50, *p* \< .001; Figure [1](#sct312577-fig-0001){ref-type="fig"}A,B). Randomized into echocardiographically indistinguishable groups, cell‐treated hearts compared to sham demonstrated rescue of cardiomyopathic traits. On average, EF postinfarction fell from 37% ± 2% to 30% ± 3% without cell treatment (CP(−); n = 25), yet recovered from 38% ± 1% to 45% ± 3% with cell therapy (CP(+); n = 25) reflecting cell‐dependent functional recovery (*p* \< .0001; Figure [1](#sct312577-fig-0001){ref-type="fig"}C). Structural compromise measured as abnormal increase in LVESV from 51 ± 5 to 69 ± 10 μl in sham contrasted (*p* \< .001) with the restoration in CP(+) hearts from 48 ± 4 μl pretherapy to 42 ± 5 μl post‐therapy (Figure [1](#sct312577-fig-0001){ref-type="fig"}D). Within age‐matched cohorts, cell therapy benefited both male and female (*p* = .81) under permanent ligation or following ischemia/reperfusion injury (*p* = .25).

![Range of stem cell therapy benefit in myocardial infarction. A, In age‐matched inbred mice devoid of heart failure risk factors, LV size demonstrated a narrow bell‐shaped distribution, underscoring homogeneity before disease initiation. B, Left anterior descending artery was ligated from a distal to a proximal site, inducing mild to severe ischemic cardiomyopathy. ST elevation on the electrocardiogram and wall motion abnormality on ultrasound confirmed anterior wall myocardial infarction. Within 1 month postinfarction, LV end‐diastolic volume increased from 43 ± 1 μl (n = 50; A) to 77 ± 4 μl (n = 50, *p* \< .001). C, Along with structural alteration (B), LV pump function, measured by ejection fraction, decreased from 68% ± 1% preinfarction to 37% ± 1% 1 month postinfarction (n = 50, *p* \< .0001). Cardiomyopathic animals were randomized into those treated with epicardial delivery of CP cells (CP(+), n = 25) and sham (CP(−), n = 25). In contrast to progressive decline in sham, ejection fraction significantly recovered with CP therapy (1 month post‐therapy, 30% ± 3% in CP(−), 45% ± 3% in CP(+), *p* \< .0001). D, Similarly, pathological chamber dilatation was reversed in CP‐treated cardiomyopathy (LV end‐systolic volume post‐therapy, 69 ± 10 μl in CP(−), 42 ± 5 μl in CP(+), *p* \< .001). E, F, Comparing pretherapy and post‐therapy unmasked individual variability in response. CP, cardiopoietic stem cells; LV, left ventricle](SCT3-9-74-g001){#sct312577-fig-0001}

Notably, individual variability was observed within the stem cell treated group (Figure [1](#sct312577-fig-0001){ref-type="fig"}E,F). Pretherapy EF---the current standard for recipient selection---did not predict the degree of functional (*p* = .15) or structural (*p* = .26) responsiveness. Rather, pretherapy LVEDV---a widely use marker of disease‐provoked pathologic remodeling---correlated with stem cell‐induced benefit, namely EF recovery (Figure [2](#sct312577-fig-0002){ref-type="fig"}A) and reverse remodeling (Figure [2](#sct312577-fig-0002){ref-type="fig"}B). Specifically, EF improvement (\>4% increase) was achieved in 70% (14/20) of the CP‐treated infarcted cohort with a pretherapy LVEDV \<100 μl. Reverse remodeling (\>15% reduction in LVESV) was achieved in 77% (10/13) of CP(+) hearts within a pretherapy LVEDV window between 65 and 100 μl.

![Effectiveness of stem cell therapy in ischemic cardiomyopathy depends on the extent of preexistent chamber dilatation. A, CP therapy‐mediated (CP(+), n = 25) recovery of LV contractility, observed during 1 month follow‐up, inversely correlated with LV size at time of intervention (pretherapy LVEDV). Disease severity was categorized based on pretherapy LVEDV into moderate (LVEDV \<65 μl, 7 CP(+), low 28% of the CP(+) cohort), advanced (65 μl \< LVEDV \<100 μl, 13 CP(+), middle 52%), and end‐stage (100 μl \< LVEDV, 5 CP(+), upper 20%). Adjusted by body weight, moderate‐, advanced‐, and end‐stage ischemic cardiomyopathy in mice corresponds to that of LVEDV \<200, 200‐370, \>370 ml, respectively in humans.[17](#sct312577-bib-0017){ref-type="ref"}, [21](#sct312577-bib-0021){ref-type="ref"}, [22](#sct312577-bib-0022){ref-type="ref"} Δ ejection fraction, change in ejection faction post‐therapy vs pretherapy; blue solid lines, predetermined criteria of improvement (\>4%) and worsening (\<−4%) in Δ ejection fraction. B, Reverse remodeling (\>15% reduction in LV end‐systolic volume) occurred in the majority of advanced stage recipients, displaying a v‐shaped relationship between Δ end‐systolic volume and pretherapy LVEDV. CP, cardiopoietic stem cells; LV, left ventricle; LVEDV, LV end‐diastolic volume](SCT3-9-74-g002){#sct312577-fig-0002}

Accordingly, disease severity was categorized based on pretherapy LVEDV into moderate (LVEDV \<65 μl, n = 14, 7 CP(−), 7 CP(+)), advanced (65 μl \< LVEDV \<100 μl, n = 26, 13 CP(−), 13 CP(+)), and end‐stage (100 μl \< LVEDV, n = 10, 5 CP(−), 5 CP(+); Figure [3](#sct312577-fig-0003){ref-type="fig"}). In moderate disease, CP therapy improved contractility (EF change, −6% ± 3% in CP(−), 8% ± 3% in CP(+), *p* \< .01) but not existing LV dilation (LVESV change, 40% ± 19% in CP(−), 13% ± 8% in CP(+), *p* = .28; Figure [3](#sct312577-fig-0003){ref-type="fig"}A,B). Advanced ischemic cardiomyopathy was the most responsive to CP‐mediated improvement, exhibiting both structural and functional restitution (EF change, −3% ± 2% in CP(−), 10% ± 2% in CP(+), *p* \< .001; LVESV change, 15% ± 11% in CP(−), −27% ± 6% in CP(+), *p* \< .01; Figure [3](#sct312577-fig-0003){ref-type="fig"}C,D). In end‐stage cardiomyopathy, CP therapy induced least benefit (EF change, −18% ± 4% in CP(−), −3% ± 4% in CP(+), *p* \< .05; LVESV change, 59% ± 12% in CP(−), −9% ± 6% in CP(+), *p* \< .01; Figure [3](#sct312577-fig-0003){ref-type="fig"}E,F).

![Grading of cardiac dilatation identifies a window of optimal response to stem cell therapy. At time of randomization (pretherapy), echocardiographic parameters were equivalent between ischemic cardiomyopathy cohorts. Prospective 1 month follow‐up (post‐therapy) validated the superiority of the CP‐treated (CP(+)) over CP‐untreated (CP(−)) cohort across all stages of cardiomyopathy, yet the effectiveness depended on the pretherapy LV volume. Specifically, in moderate cardiomyopathy (pretherapy LVEDV \<65 μl; A, B), CP therapy improved EF (−6% ± 3% in CP(−), 8 ± 3% in CP(+), *p* \< .01; A bottom), but did not change the natural course of progressive LV dilatation (A top). Advanced ischemic cardiomyopathy (65 μl \< pretherapy LVEDV \<100 μl; C, D) was most responsive to CP‐mediated improvement with both structural (C top) and functional (C bottom) restitution. In end‐stage cardiomyopathy (100 μl \< pretherapy LVEDV; E, F), cell therapy‐hampered disease progression into terminal heart failure which was unavoidable in the untreated cohort. However, CP intervention fell short in salvaging the underlying end‐stage conditions (F). CP, cardiopoietic stem cells; EF, ejection fraction; LV, left ventricle; LVEDV, LV end‐diastolic volume](SCT3-9-74-g003){#sct312577-fig-0003}

Improved EF combined with reverse remodeling are recommended goals in heart failure management,[16](#sct312577-bib-0016){ref-type="ref"} and were here achieved in \>60% of advanced (62%, 8/13), compared to ≤20% of moderate or end‐stage disease (Figure [4](#sct312577-fig-0004){ref-type="fig"}A). The molecular response within the advanced stage cohort was independently evaluated at proteomic level, where 79 proteins were found to distinguish CP‐treated from CP‐untreated infarcted hearts (Figure [4](#sct312577-fig-0004){ref-type="fig"}B). Functional enrichment analysis revealed that the CP therapy‐dependent proteome validated therapeutic responsiveness, with infarction‐provoked cardiac dilation (*p* \< .01) and contractile failure (*p* \< .01) both predicted to be mitigated on the basis of proteome remodeling, thus pinpointing the molecular reach of disease rescue.

![CP‐dependent proteome underpins advanced‐disease rescue. A, None of the untreated cohorts (CP(−)) recovered from ischemic cardiomyopathy, indicating the malignant nature of heart failure following anterior wall myocardial infarction. CP therapy (CP(+)) achieved both EF improvement and reverse remodeling, defined by \>4% absolute increase (ΔEF \> 4%) and \>15% reduction in LVESV (ΔLVESV \<−15%), respectively. These endpoints were achieved in the majority (62%, 8/13) only for the advanced stage cohort, while rarely in moderate (14%, 1/7) and end‐stage (20%, 1/5) groups. B, To decode the molecular basis of benefit, differential proteomic analysis was conducted specifically within the advanced cohort, revealing 79 differentially expressed proteins between CP(+) and CP(−), organized here by agglomerative clustering of z‐score transformed relative expression data. C, Ingenuity Pathway Analysis of these proteins independently predicted the observed functional outcomes, with significant enrichment for improvement in contractility and reversal of cardiac dilatation. CP, cardiopoietic stem cells; EF, ejection fraction; LVESV, left ventricular end‐systolic volume](SCT3-9-74-g004){#sct312577-fig-0004}

4. DISCUSSION {#sct312577-sec-0010}
=============

The present study demonstrates a window for best stem cell therapy outcomes determined within a median range of LV dilatation postinfarction. This "Goldilocks principle" was documented by leveraging standardized cell production and delivery protocols, in the setting of comorbidity‐free anterior myocardial infarction. In contrast, pretherapy EF, which has been traditionally used to recruit patients for cell therapy, did not predict recipient response.

The degree of LV dilatation has been linked to a range of efficacy experienced with pharmacological, device or surgical treatments.[23](#sct312577-bib-0023){ref-type="ref"}, [24](#sct312577-bib-0024){ref-type="ref"} It is further unmasked herein as a determinant of stem cell‐promoted cardiac repair. in vivo functional and structural restoration was reinforced by molecular validation at proteome level. The significance of LV size in prioritizing best responders is potentially applicable in practice as supported by recent clinical subanalysis in both ischemic and non‐ischemic cardiomyopathy using multiple cell types.[17](#sct312577-bib-0017){ref-type="ref"}, [21](#sct312577-bib-0021){ref-type="ref"}, [22](#sct312577-bib-0022){ref-type="ref"}, [25](#sct312577-bib-0025){ref-type="ref"} Further prospective investigation across the translational axis is now required to certify the utility of LV volumes in screening candidates for optimized regenerative biotherapy in heart failure.

5. CONCLUSION {#sct312577-sec-0011}
=============

Cell therapy benefit depends on infarction‐induced cardiac dilatation and could inform recipient stratification to maximize regenerative outcome.
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